Skip to main content

Myopathy

0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Myolex
MyolexMA - Brookline
1 program
Electrical Impedance MyographyN/A1 trial
Active Trials
NCT07502989Recruiting150Est. Sep 2027
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein MyopathyN/A1 trial
Active Trials
NCT01547767Completed2Est. Mar 2021
Philips
PhilipsNetherlands - Amsterdam
1 program
Nocturnal ventilationN/A1 trial
Active Trials
NCT01530841Completed32Est. May 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
MyolexElectrical Impedance Myography
PhilipsNocturnal ventilation
Human BioSciencesInvestigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy

Clinical Trials (3)

Total enrollment: 184 patients across 3 trials

NCT07502989MyolexElectrical Impedance Myography

Muscle Health Measurements Using Electrical Impedance Myography

Start: Apr 2025Est. completion: Sep 2027150 patients
N/ARecruiting
NCT01530841PhilipsNocturnal ventilation

Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy

Start: Jul 2012Est. completion: May 201632 patients
N/ACompleted
NCT01547767Human BioSciencesInvestigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy

Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy

Start: Feb 2012Est. completion: Mar 20212 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 184 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.